Client Charter

We are devoted to strengthening emerging pharmaceutical markets. To this end, we commit to upholding essential principles in all of our dealings with clients. Our Client Charter is our promise to you that ...

Tag Archives: pharmaceutical policy

Health insurance companies and governments use strong financial and administrative barriers to manage the utilization of new technologies. Cost-sharing (co-insurance or co-payments), prior authorization, clinical panel reviews, therapeutic reference pricing, and new technology appraisals are designed to manage the incremental uptake of new technologies. These technologies, for example, PCSK-9 inhibitors and enzyme replacement therapies, are […]

The market access landscape in the Middle East is changing rapidly. The growth of private health insurance markets in the Gulf is a significant catalyst for the re-organisation of private sector stakeholders and improvements in internal reimbursement policies. In the past, Payors were relatively generous in their reimbursement of new technologies, but in the next […]

There’s so much discussion around Big Data and Real-World Evidence (RWE) in improving access to medicines. RWE is clinical data collected after the publication of clinical trials used for marketing authorization. Sources may include health insurance claims databases, patient registries, hospital patient records, among others. Clinical trials are by design the gold standard for new […]

Around this time last year, we published a comparative review of the Pharmacoeconomic Guidelines in South Africa (PGSA) in the Journal of Medical Economics. The paper compared the PGSA with other middle- and high-income countries and concluded that they differ in important ways. The paper has been viewed 2791 times on the C&C site by […]

It’s not the type of question we’re asked every day, so it sparked our interest, particularly the assumption that something like this is possible. Opinion on the subject is divided. They range from ideas that anything related to the pharmaceutical industry is tainted, in this case the FDA, to opinions from scientists and policy experts […]

On May 10 and 11, the WHO Fair Pricing Forum met to discuss improvements to medicine pricing practices and pricing approaches that balance public health needs and incentives for pharmaceutical research and development. The Forum was established to facilitate the exchange of insights on fairer medicine pricing systems, identification of research gaps to support improvements, […]

The Spanish Ministry of Health recently rejected the use of QALYs in cost-effectiveness analyses. At issue is the subjective nature of the parameters used to develop the QALY. The Quality-Adjusted Life-Years (QALY) is a product of the change in utilities associated with a treatment multiplied by the time of treatment exposure. The QALYs gained combined […]

Journal of Medical Economics Author: Dr. João L. Carapinha, Ph.D. Objective: To compare the pharmacoeconomic guidelines in South Africa (SA) with other middle- and high-income countries. Methods: A comparative review of key features of the pharmacoeconomic guidelines in SA was undertaken using the Comparative Table of Pharmacoeconomic Guidelines developed by the International Society of Pharmacoeconomics […]

Marie-Paule Kieny, Assistant Director-General at the WHO published an interested comment on finding a comprehensive and fair solution to the price of medicines. The part that grabbed our attention was the reference to developing ” … a fair pricing model …”, see below. To that end, WHO is planning to convene governments, patient groups and […]